François Mongrain
Algemeen Directeur bij Mimetogen Pharmaceuticals, Inc.
Profiel
François Mongrain is the founder of Bellus Health (Innodia), Inc. He is currently the Director at Laurent Pharmaceuticals, Inc. and the Chief Executive & Financial Officer at Mimetogen Pharmaceuticals, Inc. Previously, he worked as a Principal at Ernst & Young LLP (Canada).
He completed his undergraduate degree at HEC Montréal.
Actieve functies van François Mongrain
Bedrijven | Functie | Begin |
---|---|---|
Mimetogen Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Algemeen Directeur | - |
Laurent Pharmaceuticals, Inc.
Laurent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada. | Directeur/Bestuurslid | - |
Eerdere bekende functies van François Mongrain
Bedrijven | Functie | Einde |
---|---|---|
Ernst & Young LLP (Canada)
Ernst & Young LLP (Canada) Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP (Canada) engages in the provision of consulting, assurance, tax, and transaction services. The company is headquartered in Toronto, Canada. | Corporate Officer/Principal | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Oprichter | - |
Opleiding van François Mongrain
HEC Montréal | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Health Technology |
Ernst & Young LLP (Canada)
Ernst & Young LLP (Canada) Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP (Canada) engages in the provision of consulting, assurance, tax, and transaction services. The company is headquartered in Toronto, Canada. | Commercial Services |
Mimetogen Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |
Laurent Pharmaceuticals, Inc.
Laurent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada. | Health Technology |